Fulgent Genetics (FLGT) Receivables (2015 - 2026)

Fulgent Genetics has disclosed Receivables across 12 years of filings, most recently posting $66.4 million for Q2 2026.

• In Q2 2026, Receivables fell 16.21% year-over-year to $66.4 million; the TTM figure through Jun 2026 stood at $66.4 million (down 16.21% YoY), while the FY2025 annual figure was $85.9 million, up 21.34% from the prior year.
• Receivables came in at $66.4 million for Q2 2026 at Fulgent Genetics, down from $70.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $161.8 million in Q1 2022 to a low of $19.9 million in Q4 2022.
• Average Receivables over 5 years is $71.8 million, with a median of $68.4 million recorded in 2026.
• Year-over-year, Receivables tumbled 85.71% in 2022 and jumped 163.19% in 2023.
• Over 5 years, Receivables stood at $19.9 million in 2022, then jumped by 163.19% to $52.5 million in 2023, then surged by 34.96% to $70.8 million in 2024, then rose by 21.34% to $85.9 million in 2025, then slipped by 22.7% to $66.4 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $66.4 million in Q2 2026, $70.4 million in Q1 2026, and $85.9 million in Q4 2025.